Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 4/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
| ▸ | VNN1 | O95497 | 2/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 3/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.42 |
| ▸ | MGLL | Q99685 | 2/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708152 | 0.82 | CYP2D6 (0.56) | — | |
| SCHEMBL6705835 | 0.81 | OPRD1 (0.41) | VNN1PARP14PARP10MGLLNAMPT | |
| SCHEMBL6706030 | 0.80 | MAPT (0.49) | ADRA1DADRA1AADRA1BACKR3 | |
| SCHEMBL6698019 | 0.77 | NAMPT (0.62) | PARP14PARP10NAMPTPARP1 | |
| SCHEMBL6694937 | 0.75 | ITGB3 (0.56) | — | |
| SCHEMBL24628679 | 0.75 | HPGDS (0.45) | PARP14PARP10AOC3PARP1 | |
| Hydrochloric Acid SCHEMBL6700195 | 0.74 | ITGB3 (0.55) | — | |
| SCHEMBL6698110 | 0.74 | ALDH1A1 (0.55) | — | |
| SCHEMBL6706867 | 0.74 | HSD11B1 (0.48) | PARP14PARP10 | |
| SCHEMBL6706780 | 0.74 | PANK3 (0.49) | ACKR3NAMPTPANK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-02-05 | — | — | US | disclosed |
| EP-1289971-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001092241-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 AND MTP INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024215-A1 | Benzamide derivatives and their use as apob-100 and mtp inhibitors | APOB, APOL1, CETP | ADRA1D 1573/4885ADRA1A 1350/4885ADRA2B 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.